Tim Friede has been bitten by over 200 snakes to develop immunity.
His antibodies are being used to create a broad-spectrum antivenom by Centivax.
The antivenom has shown full protection against 13 snake species and partial protection against six in mice trials.
Clinical trials on dogs with snakebite injuries are planned in Australia.
This research could revolutionize snakebite treatment, saving thousands of lives annually.
Why this matters: Snakebites cause between 80,000 and 100,000 deaths worldwide each year. A universal antivenom could significantly reduce this number and improve treatment outcomes.
Tim Friede's journey began in 2001 with the goal of creating a better treatment for snakebites, which affect millions and cause numerous deaths and disabilities annually. Existing antivenoms, developed by injecting horses with venom, carry the risk of anaphylactic shock due to foreign equine proteins.
Friede started by injecting himself with diluted cobra venom, gradually increasing the concentration. He then progressed to live snake bites, facing near-fatal consequences, including a four-day coma after being bitten by cobras. Despite the risks and pain, Friede persisted, collaborating with scientists and undergoing numerous studies to understand his immune response.
Centivax, led by Jacob Glanville, extracted DNA from Friede's B-cells to clone his IgG antibodies. This led to the discovery that Friede's antibodies could neutralize venom from snakes he had never even been exposed to, such as the king cobra. The resulting antivenom cocktail, combining Friede’s antibodies with a toxin-blocking drug, has shown promising results in animal trials.
The next step involves testing the antivenom on dogs in Australia who have been brought in for snake bite injuries, with hopes of extending the treatment to viper bites. This research represents a significant advancement in snakebite treatment, potentially offering a more effective and safer alternative to traditional antivenoms.
Q: How did Tim Friede become immune to snake venom?
He injected himself with increasing doses of snake venom over time, allowing his body to develop antitoxin antibodies.
Q: What is Centivax?
Centivax is a biotech company that is developing a universal antivenom based on Tim Friede's antibodies.
Q: How effective is the new antivenom?
In mice trials, the antivenom provided full protection against 13 snake species and partial protection against six more.
A universal antivenom could save thousands of lives each year by providing a more effective treatment for snakebites.
Tim Friede's self-experimentation has paved the way for this breakthrough.
Clinical trials are underway to test the antivenom on animals, with hopes of eventually using it in humans.
The new antivenom may offer a safer alternative to traditional antivenoms, which can cause allergic reactions.
Do you think this research will lead to a truly universal antivenom? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Towering talipot palms in a Rio de Janeiro park are flowering for the first and only time in their lives. These palms, introduced by landsca...
Reports of blue-furred dogs roaming Chernobyl’s Exclusion Zone caused a stir, leading to concerns about radiation exposure. However, the act...
A recent 5.2-magnitude earthquake in Southern California provided a fascinating glimpse into animal behavior, as a herd of elephants at the ...
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer